The Semaglutide Pill for Weight Loss: What It Is and Whether It's Right for You

How the semaglutide pill actually works day to day

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. It mimics a gut hormone that signals fullness to the brain, slows how quickly the stomach empties and, over time, reduces overall appetite. The tablet version co-formulates the medicine with an absorption enhancer called SNAC, which allows it to cross the stomach lining into the bloodstream, something most protein-based medicines cannot do when swallowed.

The daily routine matters: the tablet is taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120 ml). You then wait at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines. The MHRA's approval details, alongside the full prescribing information, are published on the electronic Medicines Compendium and are worth reading before starting.

No refrigeration is required. That matters more than it sounds: the weekly injection pens need to be kept at 2–8°C, which limits spontaneity when you're away from home. If you travel frequently or your work pattern makes cold storage awkward, the tablet side-steps all of that. Tuck it next to your bedside glass of water the night before and it's just another part of the morning.

For a fuller look at the tablet's approval and what distinguishes it from other options, our Wegovy pill overview covers the background in detail.

What the trial results mean in practice (and the honest caveats

The headline figure from the OASIS 4 trial is an average body-weight reduction of around 13.6% over 64 weeks, compared with roughly 2.4% in the placebo group) an impressive difference. Among participants who stayed fully adherent to treatment throughout, the average loss rose to approximately 17%. Both figures come from a phase-3 study of 307 adults with obesity or overweight plus at least one weight-related condition, and they reflect results alongside a reduced-calorie diet and increased physical activity. Adherence to the morning routine in particular (taking the tablet correctly, on an empty stomach, every day) seems to influence how much benefit people see.

The most common side effects in the trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation were reported more frequently in the treatment group than in the placebo group. Most were mild to moderate and eased as treatment continued, which mirrors the pattern seen with the injection form. Starting at 1.5 mg and titrating slowly is part of how that is managed.

These are clinically meaningful results, but they are population averages. Individual response varies, and no medicine produces the same outcome for everyone. The semaglutide tablets page looks at the evidence in more depth if you want the fuller picture before making a decision.

Who the tablet is licensed for, and who should think carefully

The MHRA licensed the Wegovy tablet for adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, your prescriber will apply the appropriate threshold when assessing you.

The tablet is not recommended during pregnancy, while breastfeeding, or when trying to conceive. It is not licensed for anyone under 18. Certain medical histories (including a history of pancreatitis or specific thyroid conditions) require careful prescriber assessment before it could be considered appropriate. The MHRA has separately noted that GLP-1 medicines are not evaluated for cosmetic or rapid weight loss, and eligibility always rests on a clinical picture rather than a number on a scale alone.

Patients already established on the 2.4 mg weekly injection may be able to move directly to the 25 mg tablet, subject to clinical assessment, rather than starting from the lowest tablet dose. Whether that applies in your case is a conversation for a prescriber, not a decision to make independently. If you're trying to understand the full range of licensed options, our treatment overview sets out how the different approaches compare.

Getting a prescription for the oral semaglutide pill in the UK

The Wegovy tablet is a prescription-only medicine. There is no legal route to it without a clinical assessment carried out by a qualified prescriber. That assessment exists for good reasons: a prescriber checks your medical history, current medicines, BMI, and any contraindications before issuing a prescription. A question our prescribers hear often is whether semaglutide pills obtained through the online route are genuinely safe. The short answer is yes, if the pharmacy is registered with the GPhC, you can verify any online pharmacy on the GPhC register, including us.

The MHRA has also made clear that GLP-1 medicines sold without a prescription or through unverified online sellers carry serious risks, fake pens and tablets have been seized in the UK in significant quantities. Verifying your pharmacy and confirming a real clinical assessment sits at the front of it takes two minutes and removes that risk entirely. It is also worth understanding that the pill form of semaglutide has specific absorption requirements that counterfeit or unverified products are unlikely to meet, which is another reason to use a regulated provider.

The NHS does not currently fund the Wegovy tablet: a NICE appraisal would be required before it could enter NHS commissioning, and none has been completed. Private prescription is the only route at this stage. For a straightforward look at what that costs and what's included, the Wegovy pill cost page breaks it down. If you'd like to find out whether you're clinically suitable and want background on the new semaglutide pill before speaking to a prescriber, starting a free consultation with our prescribers is the next step.